出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/02/12 15:07:41」(JST)
Systematic (IUPAC) name | |
---|---|
(2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5- (diaminomethylideneamino)-1-oxopentan-2-yl]-1- |
|
Clinical data | |
Trade names | Ddavp, Minirin, Minirin Melt, Octim, Stimate |
AHFS/Drugs.com | monograph |
Pregnancy
category |
|
Legal status |
|
Routes | IV, IM, SC, intranasal, oral |
Pharmacokinetic data | |
Bioavailability | Variable; 0.08–0.16% (oral) |
Protein binding | 50% |
Half-life | 1.5–2.5 hours |
Excretion | Renal |
Identifiers | |
CAS number | 16679-58-6 Y |
ATC code | H01BA02 |
PubChem | CID 5311065 |
DrugBank | DB00035 |
ChemSpider | 10481973 Y |
UNII | ENR1LLB0FP Y |
KEGG | D00291 Y |
ChEMBL | CHEMBL376685 Y |
Chemical data | |
Formula | C46H64N14O12S2 |
Molecular mass | 1069.22 g/mol |
SMILES
|
|
InChI
|
|
Y (what is this?) (verify) |
Desmopressin (trade names: DDAVP, DesmoMelt, Minirin, Minirin Melt, Octim, Stimate) is a synthetic replacement for vasopressin, the hormone that reduces urine production. It may be taken nasally, intravenously, or as an oral or sublingual tablet. Physicians prescribe desmopressin most frequently for treatment of diabetes insipidus, bedwetting, or nocturia.
Desmopressin (1-desamino-8-D-arginine vasopressin) is a man-made form of the normal human hormone arginine vasopressin (the antidiuretic hormone, or ADH), a peptide containing nine amino acids and so on.
Compared to vasopressin, desmopressin's first amino acid has been deaminated, and the arginine at the eighth position is in the dextro rather than the levo form (see stereochemistry).
Desmopressin is used to treat nocturnal enuresis (bedwetting). It is usually prescribed in the form of oral desmopressin acetate, DDAVP.People taking DDAVP are 4.5 times more likely to sleep without disruption compared with placebo.[1][2]
US drug regulators banned treating nocturnal enuresis with desmopressin nasal sprays after two patients died and fifty-nine other patients suffered seizures. The patients were using desmopressin when they developed hyponatremia, an imbalance of the body's sodium levels.[3]
Desmopressin has some benefit in adults who have problems with night time urination (known as nocturia).[4]
Desmopressin can be used to promote the release of von Willebrand factor (with subsequent increase in factor VIII survival secondary to vWF complexing) in patients with coagulation disorders such as von Willebrand disease, mild hemophilia A (factor VIII deficiency), and thrombocytopenia. It can be used with uremic induced platelet dysfunction. It is not effective in the treatment of hemophilia B (factor IX deficiency) or severe hemophilia A.
Desmopressin is used in the treatment of central diabetes insipidus (DI), to replace endogenous ADH that is missing in the central nervous system type of this disorder (decreased production of ADH from the posterior pituitary). It is also used in the diagnostic workup for diabetes insipidus, in order to distinguish central from nephrogenic DI.
FDA regulators have said that desmopressin tablets can still be considered safe for treatment of nocturnal enuresis as long as the patient is otherwise healthy. Patients must stop taking desmopressin if they develop severe vomiting and diarrhea, fever, the flu, or severe cold. Patients should also be very cautious about taking desmopressin during hot weather conditions or following strenuous exercise, as these conditions can place stress on the body's salt and water balance.
A healthy body needs to maintain a balance of water and salt (sodium). If sodium levels become too low (hyponatremia) – either as a result of increased water take-up or reduced salt levels – a person may have seizures and, in extreme cases, may die.[5]
Desmopressin works by limiting the amount of water that is eliminated in the urine. It works at the level of the renal collecting duct by binding to V2 receptors, which signal for the translocation of aquaporin channels via cytosolic vesicles to the apical membrane of the collecting duct. The presence of these aquaporin channels in the distal nephron causes increasing water reabsorption from the urine, which becomes passively re-distributed from the nephron to systemic circulation by way of basolateral membrane channels.[6] Desmopressin also stimulates release of von Willebrand factor from endothelial cells by acting on the V2 receptor.
Desmopressin is degraded more slowly than recombinant vasopressin, and requires less frequent administration. In addition, it has little effect on blood pressure, while vasopressin may cause arterial hypertension. Vasopressin stimulates the release of ACTH, which indirectly increases responsiveness of alpha-1 receptor in blood vessel smooth muscle, increasing vessel tone and blood pressure. Desmopressin does not stimulate ACTH release, and therefore does not directly raise blood pressure.[citation needed]
|
|
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
国試過去問 | 「103I067」「100F038」「109I025」 |
リンク元 | 「尿崩症」「デスモプレシン」「デスモプレシン負荷試験」「desmopressin」 |
拡張検索 | 「DDAVP試験」 |
A
※国試ナビ4※ [103I066]←[国試_103]→[103I068]
E
※国試ナビ4※ [100F037]←[国試_100]→[100F039]
D
※国試ナビ4※ [109I024]←[国試_109]→[109I026]
多尿 3000ml/day | ||||
↓ | ||||
尿浸透圧 | → |
→ 290 mOsm/kg以上 |
→ |
浸透圧利尿 |
↓ | ||||
↓水利尿 | ||||
↓ | ||||
血清ナトリウム濃度 血清レニン濃度 |
→ |
→ 低値 |
→ |
心因性多飲 |
↓ | ||||
↓正常上限~軽度上昇 | ||||
↓ | ||||
水制限テスト バソプレシンテスト |
→ |
→ 尿量不変、尿浸透圧不変 |
→ |
腎性尿崩症 |
↓ | ||||
↓尿量減少、尿浸透圧上昇 | ||||
↓ | ||||
バソプレシン濃度(高張食塩水負荷時) MRIで基礎疾患の描出・T1で下垂体後葉の高信号の消失 |
||||
↓ | ||||
中枢性尿崩症 |
-diabetes insipidus
I. NATURALLY OCCURRING VASOPRESSIN-LIKE PEPTIDES? | |||||
??A. Vertebrates? | A? | W? | X? | Y? | Z? |
????1. Mammals | |||||
??????? Arginine? vasopressin* (AVP) (human beings and other mammals) | NH2 | Tyr | Phe | Gln | Arg |
???????Lypressin* (pigs, marsupials) | NH2 | Tyr | Phe | Gln | Lys |
???????Phenypressin (macropodids) | NH2 | Phe | Phe | Gln | Arg |
????2. Nonmammalian vertebrates | |||||
Vasotocin | NH2 | Tyr | Ile | Gln | Arg |
??B. Invertebrates? | |||||
????1. Arginine conopressin (Conus striatus)? | NH2 | Ile | Ile | Arg | Arg |
????2. Lysine conopressin (Conus geographicus)? | NH2 | Phe | Ile | Arg | Lys |
????3. Locust subesophageal ganglia peptide | NH2 | Leu | Ile | Thr | Arg |
II. SYNTHETIC VASOPRESSIN PEPTIDES? | |||||
??A. V1-selective agonists? | |||||
????1. V1a-Selective Agonist [Phe2, Ile3, Orn8]AVP | NH2 | Phe | Ile | Gln | Orn |
????2. V1b-Selective Agonist Deamino [D-3-(3'-pyridyl)-Ala2]AVP | H | D-3-(3'-pyridyl)-Ala2 | Phe | Gln | Arg |
??B. V2-selective agonists? | |||||
????1. Desmopressin* (DDAVP) | H | Tyr | Phe | Gln | D-Arg? |
????2. Deamino[Val4, D-Arg8]AVP | H | Tyr | Phe | Val | D-Arg? |
III. NONPEPTIDE AGONIST? | |||||
A. OPC-51803? |